2013
DOI: 10.1155/2013/907189
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Infliximab on the UVB-Induced Apoptosis of Keratinocytes Infected by HPV38 E6/E7

Abstract: The question of the effect of anti-TNF-alpha in skin carcinogenesis is especially relevant in view of the increased use of these drugs for the treatment of autoinflammatory immune diseases. Since ultraviolet radiation and human papillomavirus are involved in skin carcinogenesis, we wished to investigate the effect of TNF-alpha antagonists on the UVB-induced apoptosis of keratinocytes infected by HPV38. Our results indicate that anti-TNF agent, infliximab, does not contribute to the survival of HPV38-transduced… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 13 publications
0
1
0
Order By: Relevance
“…A day after the passage, cells received fresh growth medium supplemented with/without TNFα (10 ng/mL; Sigma-Aldrich, Munich, Germany) or TNFα and infliximab (IFX) (200 μg/ mL; Centocor Biotech Inc., County Cork, Ireland). Dose of infliximab was determined in pilot experiments based on the dose range of already published data [20,21]. The stimulation time with TNFα alone or TNFα/IFX was 24 h. Then, cells were further treated for 18 h with soluble, human, recombinant TRAIL (KillerTRAIL, Alexis, Gruenberg, Germany ALX-201-073-C020; 30 ng/mL or 30, 15, 7.5 ng/mL for dose-dependent experiment), or for 48 h with 5FU (40 μmol; Sigma-Aldrich, Munich, Germany).…”
Section: Cell Lines and Cell Culture Conditionsmentioning
confidence: 99%
“…A day after the passage, cells received fresh growth medium supplemented with/without TNFα (10 ng/mL; Sigma-Aldrich, Munich, Germany) or TNFα and infliximab (IFX) (200 μg/ mL; Centocor Biotech Inc., County Cork, Ireland). Dose of infliximab was determined in pilot experiments based on the dose range of already published data [20,21]. The stimulation time with TNFα alone or TNFα/IFX was 24 h. Then, cells were further treated for 18 h with soluble, human, recombinant TRAIL (KillerTRAIL, Alexis, Gruenberg, Germany ALX-201-073-C020; 30 ng/mL or 30, 15, 7.5 ng/mL for dose-dependent experiment), or for 48 h with 5FU (40 μmol; Sigma-Aldrich, Munich, Germany).…”
Section: Cell Lines and Cell Culture Conditionsmentioning
confidence: 99%